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http://dx.doi.org/10.1016/j.cgh.2016.07.008For busy physicians there are often delays inincorporating the latest clinical trial evidence into
their treatment protocols for patients with inﬂammatory
bowel disease (IBD). To address this challenge an in-
ternational faculty of IBD leaders, chaired by William
Sandborn, MD, of the IBD Center at the University of
California San Diego, was assembled to conduct a sys-
tematic clinical appraisal of the medical literature, distill
the evidence, and assess the relative strengths and lim-
itations of current knowledge. To structure the faculty
data reviews, thought-provoking statements were devel-
oped regarding anti–tumor necrosis factor-a therapy
during the operative period, thiopurines as monother-
apy, whether anti–tumor necrosis factor-a agents
possess a disease-modifying effect, the safety of combina-
tion therapy, the withdrawal of therapy in patients in
remission, and the place of anti-integrins in IBD therapy.
In parallel, an online clinical practice survey of interna-
tional gastroenterologists (GIs) was conducted by the
publisher of Clinical Gastroenterology and Hepatology,
based on the same thought-provoking statements posed
to the faculty for their data reviews, to discover and
document gaps between the published evidence and clin-
ical practice. The survey respondents were asked to vote
on each statement, using a 5-point Likert scale of accep-
tance or rejection. The IBD faculty were then convened to
critically discuss their medical literature reviews relating
to each statement and vote on the validity and evidence
base of the statements, using the same Likert scale as the
survey, followed by systematic discussion and analysis of
the voting results from the GI survey and the faculty data
reviews. Insufﬁcient data, ﬂawed controlled trials, and
inconsistent deﬁnitions within the IBD arena generated
considerable debate among the IBD faculty, regarding
various aspects of each statement. Most of the interna-
tional GIs who responded to the survey spend 11%
of their time managing patients with IBD, and informa-
tion gleaned from this exercise should provide areasfor future discussion and research, and possible applica-
tion to evidence-based practice to further improve man-
agement and outcomes for patients with IBD in the
immediate future. Both faculty and survey voting results
for all 8 statements are presented in this online publica-
tion (http://education.cghjournal.org/video.php?event_
id¼1640&stage_id¼5&vcs¼1), and the interactive publi-
cation format provides readers with the opportunity to
compare their practice patterns and views with those
of peers and the faculty of IBD leaders.
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